Lamellarin D: A Novel Potent Inhibitor of Topoisomerase I

Cancer Research

Volumn 63, Issue 21, 2003, Pages 7392-7399

  Facompré, Michaël ^a   Tardy, Christelle ^a   Bal Mahieu, Christine ^a   Colson, Pierre ^b   Perez, Carlos ^c   Manzanares, Ignacio ^c   Cuevas, Carmen ^c   Bailly, Christian ^a,d  

^a CENTRE OSCAR LAMBRET   (France)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c PHARMAMAR S A   (Spain)

^d INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

6H [1]BENZOPYRANO[4',3':4,5]PYRROLO[2,1 A]ISOQUINOLIN ONE; ALKALOID; CAMPTOTHECIN; DNA TOPOISOMERASE INHIBITOR; ISOQUINOLINE DERIVATIVE; LAM 501; LAMELLARIN D; UNCLASSIFIED DRUG;

ABSORBANCE SPECTROSCOPY; ANIMAL CELL; ARTICLE; ASCIDIACEA; CONTROLLED STUDY; COVALENT BOND; CROSS RESISTANCE; CYTOTOXICITY; DNA CLEAVAGE; DNA SEQUENCE; DNA SUPERCOILING; DRUG DNA BINDING; DRUG POTENCY; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; FLUORESCENCE SPECTROSCOPY; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; INTERCALATION COMPLEX; LINEAR DICHROISM; MOLECULAR MODEL; MOLLUSC; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DNA BINDING; SPECTROSCOPY;

ANIMALS; ANTINEOPLASTIC AGENTS; CATTLE; COUMARINS; DNA; DNA TOPOISOMERASES, TYPE I; ENZYME INHIBITORS; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; ISOQUINOLINES; LEUKEMIA P388; MICE; MODELS, MOLECULAR;

EID: 0242526064     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Pommier, Y. Diversity of DNA topoisomerases I and inhibitors. Biochimie, 80: 255-270, 1998.
2. Bailly, C. Topoisomerase I poisons and suppressors as anticancer drugs. Curr. Med. Chem., 7: 39-58, 2000.
3. Nitiss, J. L. DNA topoisomerases in cancer chemotherapy: using enzymes to generate selective DNA damage. Curr. Opin. Investig. Drugs, 3: 1512-1516, 2002.
4. Garcia-Carbonero, R., and Supko, J. G. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin. Cancer Res., 8: 641-661, 2002.
5. Zunino, F., Dallavalleb, S., Laccabuea, D., Berettaa, G., Merlinib, L., and Pratesi, G. Current status and perspectives in the development of camptothecins. Curr. Pharm. Des., 8: 2505-2520, 2002.
6. Bailly, C. Homocamptothecins: potent topoisomerase I inhibitors and promising anticancer drugs. Crit. Rev. Oncol. Hematol., 45: 91-108, 2003.
7. Bailly, C. Targeting DNA and topoisomerase I with indolocarbazole antitumor agents. In: M. Demeunynck, C. Bailly, and W. D. Wilson (eds.), Small Molecule DNA and RNA Binders, Vol. 2, pp. 538-575. Wiley-VCH: Weinheim, Germany, 2003.
8. Long, B. H., and Balasubramanian, B. N. Non-camptothecin topoisomerase I compounds as potential anticancer agents. Exp. Opin. Ther. Patents, 10: 635-666, 2000.
9. Meng, L. H., Liao, Z. Y., and Pommier, Y. Non-camptothecin DNA topoisomerase I inhibitors in cancer therapy. Curr. Top. Med. Chem., 3: 305-320, 2003.
10. Andersen, R. J., Faulkner, D. J., He, C-H., Van Duyne, G. D., and Clardy, J. Metabolites of the marine prosobranch mollusk Lamellaria sp. J. Am. Chem. Soc., 107: 5492-5495, 1985.
11. Davis, R. A., Carroll, A. R., Pierens, G. K., and Quinn, R. J. New lamellarin alkaloids from the Australian ascidian, Didemnum chartaceum. J. Nat. Prod., 62: 419-424, 1999.
12. Quesada, A. R., Garcia Gravalos, M. D., and Fernandez Puentes, J. L. Polyaromatic alkaloids from marine invertebrates as cytotoxic compounds and inhibitors of multidrug resistance caused by P-glycoprotein. Br. J. Cancer, 74: 677-682, 1996.
13. Banwell, M. G., and Hockless, D. Convergent total synthesis of lamellarin K. Chem. Commun., 23: 2259-2260, 1997.
14. Houssier, C., and O'Konski, C. T. Electro-optical instrumentation systems with their data acquisition and treatment. In: S. Krause (ed.), Molecular Electro-Optics, pp. 309-339. New York: Plenum Publishing Corporation, 1981.
15. Colson, P., Bailly, C., and Houssier, C. Electric linear dichroism as a new tool to study sequence preference in drug binding to DNA. Biophys. Chem., 58: 125-140, 1996.
16. Rossi, F., Labourier, E., Forné, T., Divita, G., Derancourt, J., Riou, J. F., Antoine, E., Cathala, G., Brunel, C., and Tazi, J. Specific phosphorylation of SR proteins by mammalian DNA topoisomerase 1. Nature (Lond.), 381: 80-82, 1996.
17. Bailly, C. DNA relaxation and cleavage assays to study topoisomerase I inhibitors. Methods Enzymol., 340: 610-623, 2001.
18. Faircloth, G. T., Stewart, D., and Clement, J. J. A simple screening procedure for the quantitative measurement of cytotoxicity assay. J. Tissue Cult. Methods, 11: 201-205, 1988.
19. Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenney, S., and Boyd, M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. (Bethesda), 82: 1107-1112, 1990.
20. Madelaine, J., Prost, S., Naudin, A., Riou, G., Lavelle, F., and Riou, J. F. Sequential modifications of topoisomerase I activity in a camptothecin resistant cell line established by progressive adaptation. Biochem. Pharmacol., 45: 339-348, 1993.
21. Cory, A. H., Owen, T. C., Barltrop, J. A., and Cory, J. G. Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays. Cancer Commun., 3: 207-212, 1991
22. Staker, B. L., Hjerrild, K., Feese, M. D., Behnke, C. A., Burgin, A. B., Jr., and Stewart, L. The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc. Natl. Acad. Sci. USA, 99: 15387-15392, 2002.
23. Cornell, W. D., Cieplak, P., Bayly, C. I., Gould, I. R., Merz, K. M. J., Ferguson, D. M., Spellmeyer, D. C., Fox, T., Caldwell, J. W., and Kollman, R. A. A second generation force field for the simulation of proteins and nucleic acids. J. Am. Chem. Soc., 177: 5179-5197, 1995.
24. Gasteiger, J., and Marsili, M. Iterative partial equalization of orbital electronegativity - a rapid access to atomic charges. Tetrahedron, 36: 3219-3928, 1980.
25. Morris, G. M., Goodsell, D. S., Halliday, R. S., Huey, R., Hart, W. E., Belew, R. K., and Olson, A. J. Automated docking using a Lamarckian genetic algorithm and a empirical binding free energy function. J. Comput. Chem., 19: 1639-1662, 1988.
26. Ishibashi, F., Tanabe, S., Oda, T., and Iwao, M. Synthesis and structure-activity relationship study of lamellarin derivatives. J. Nat. Prod., 65: 500-504, 2002.
27. Trask, D. K., and Muller, M. T. Stabilization of type I topoisomerase-DNA covalent complexes by actinomycin D. Proc. Natl. Acad. Sci. USA, 85: 1417-1421, 1988.
28. Bailly, C., Carrasco, C., Hamy, F., Vezin, H., Prudhomme, M., Saleem, A., and Rubin, E. The camptothecin-resistant topoisomerase I mutant F361S is cross-resistant to antitumor rebeccamycin derivatives. A model for topoisomerase I inhibition by indolocarbazoles. Biochemistry, 38: 8605-8611, 1999.
29. Pilch, B., Allemand, E., Facompré, M., Bailly, C., Riou, J. F., Soret, J., and Tazi, J. Specific inhibition of SR splicing factors phosphorylation, spliceosome assembly and splicing by the anti-tumor drug NB506. Cancer Res., 61: 6876-6884, 2001.
30. Fujimori, A., Harker, W. G., Kohlhagen, G., Hoki, Y., and Pommier, Y. Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin. Cancer Res., 55: 1339-1346, 1995.
31. Takebayashi, Y., Pourquier, P., Yoshida, A., Kohlagen, G., and Pommier, Y. Poisoning of human DNA topoisomerase I by ecteinascidin 743, an anticancer drug that selectively alkylates DNA in the minor groove. Proc. Natl. Acad. Sci. USA, 96: 7196-7201, 1999.
32. Kokoshka, J. M., Capson, T. L., Holden, J. A., Ireland, C. M., and Barrows, L. R. Differences in the topoisomerase I cleavage complexes formed by camptothecin and wakayin, a DNA-intercalating marine natural product. Anticancer Drugs, 7: 758-765, 1996.
33. Dassonneville, L., Wattez, N., Baldeyrou, B., Mahieu, C., Lansiaux, A., Banaigs, B., Bonnard, I., and Bailly, C. Inhibition of topoisomerase II by the marine alkaloid ascididemin and induction of apoptosis in leukemia cells. Biochem. Pharmacol., 60: 527-537, 2000.
34. Peschko, C., Winklhofer, C., and Steglich, W. Alkaloids from marine organisms, part 5. Biomimetic total synthesis of lamellarin L by coupling of two different arylpyruvic acid units. Chem. Eur. J., 6: 1147-1152, 2000.
35. Ridley, C. P., Reddy, M. V., Rocha, G., Bushman, F. D., and Faulkner, D. J. Total synthesis and evaluation of lamellarin α20-sulfate analogues. Bioorg. Med. Chem., 10: 3285-3290, 2002.
36. Ploypradith, P., Jinaglueng, W., Pavaro, C., and Ruchirawat, S. Further developments in the synthesis of lamellarin alkaloids via direct metal-halogen exchange. Tetrahedron Lett., 44: 1363-1366, 2003.
37. Bailly, C., Dassonneville, L., Colson, P., Houssier, C., Fukasawa, K., Nishimura, S., and Yoshinari, T. Intercalation into DNA is not required for inhibition of topoisomerase I by indolocarbazole antitumor agents. Cancer Res., 59: 2853-2860, 1999.
38. Kohlhagen, G., Paull, K. D., Cushman, M., Nagafuji, P., and Pommier, Y. Protein-linked DNA strand breaks induced by NSC 314622, a novel noncamptothecin topoisomerase I poison. Mol. Pharmacol., 54: 50-58, 1998.
39. Bailly, C., Lansiaux, A., Dassonneville, L., Demarquay, D., Coulomb, H., Huchet, M., Lavergne, O., and Bigg, D. C. H. Homocamptothecin, an E-ring modified camptothecin analog, generates new topoisomerase I-mediated DNA breaks. Biochemistry, 38: 15556-15563, 1999.
40. Yao, S., Murali, D., Seetharamulu, P., Haridas, K., Petluru, P. N. V., Reddy, D. G., and Hausheer, F. H. Topotecan lactone selectively binds to double- and single-stranded DNA in the absence of topoisomerase I. Cancer Res., 58: 3782-3786, 1998.